UNIVERSI
TÄ
TS-
BIBLIOTHEK
P
ADERBORN
Anmelden
Menü
Menü
Start
Hilfe
Blog
Weitere Dienste
Neuerwerbungslisten
Fachsystematik Bücher
Erwerbungsvorschlag
Bestellung aus dem Magazin
Fernleihe
Einstellungen
Sprache
Deutsch
Deutsch
Englisch
Farbschema
Hell
Dunkel
Automatisch
Sie befinden Sich nicht im Netzwerk der Universität Paderborn. Der Zugriff auf elektronische Ressourcen ist
gegebenenfalls
nur via VPN oder Shibboleth (DFN-AAI) möglich.
mehr Informationen...
Universitätsbibliothek
Katalog
Suche
Details
Zur Ergebnisliste
Datensatz exportieren als...
BibTeX
Zonisamide improves wearing-off in Parkinson's disease: A randomized, double-blind study
Movement disorders, 2015-09, Vol.30 (10), p.1343-1350
Murata, Miho
Hasegawa, Kazuko
Kanazawa, Ichiro
Fukasaka, Junichi
Kochi, Kenji
Shimazu, Rieko
2015
Volltextzugriff (PDF)
Details
Autor(en) / Beteiligte
Murata, Miho
Hasegawa, Kazuko
Kanazawa, Ichiro
Fukasaka, Junichi
Kochi, Kenji
Shimazu, Rieko
Titel
Zonisamide improves wearing-off in Parkinson's disease: A randomized, double-blind study
Ist Teil von
Movement disorders, 2015-09, Vol.30 (10), p.1343-1350
Ort / Verlag
United States: Blackwell Publishing Ltd
Erscheinungsjahr
2015
Quelle
Wiley Online Library - AutoHoldings Journals
Beschreibungen/Notizen
Background Previously, we reported 50 mg/d zonisamide improved wearing‐off without increasing dyskinesia in patients with Parkinson's disease (PD). Methods To determine the efficacy of zonisamide for treatment of “off” time in PD patients, we conducted a multicenter, randomized, double‐blind, parallel‐group, placebo‐controlled study in Japan. Patients with PD and wearing‐off received placebo for 4 weeks and then were treated for 12 weeks with zonisamide 25 or 50 mg/d or placebo, in addition to their previous therapy. The primary endpoint was the change from baseline in daily “off” time as determined by patients’ diaries at the final assessment. Secondary endpoints included changes from baseline in the total scores of the Unified Parkinson's Disease Rating Scale Parts I, II, III, and IV, the dyskinesia duration, and PDQ‐39 score. Results Of 422 patients enrolled, 389 (131 for placebo, 130 for zonisamide 25 mg, and 128 for zonisamide 50 mg) were randomized, and 354 (120, 119, and 115, respectively) completed the study. The “off” time significantly reduced by 0.719 ± 0.179 h for zonisamide, 50 mg compared with placebo (0.011 ± 0.173 h, P = 0.005). Although the incidence of somnolence was higher for zonisamide (3.1% for zonisamide 25 mg, 6.3% for zonisamide 50 mg) than for placebo (2.3%), the incidences of the other adverse events, including dyskinesia or hallucination, for both zonisamide treatments were comparable to those for placebo. Conclusion The study provides evidence that confirms the efficacy of zonisamide 50 mg/d for reduction in “off” time in PD patients with wearing‐off phenomena. © 2015 International Parkinson and Movement Disorder Society
Sprache
Englisch
Identifikatoren
ISSN: 0885-3185
eISSN: 1531-8257
DOI: 10.1002/mds.26286
Titel-ID: cdi_proquest_miscellaneous_1717498658
Format
–
Schlagworte
Aged
,
Anticonvulsants - administration & dosage
,
Anticonvulsants - adverse effects
,
Anticonvulsants - pharmacology
,
Dopamine Agents - administration & dosage
,
Dopamine Agents - adverse effects
,
Dopamine Agents - pharmacology
,
Double-Blind Method
,
Drug Therapy, Combination
,
Female
,
Humans
,
Isoxazoles - administration & dosage
,
Isoxazoles - adverse effects
,
Isoxazoles - pharmacology
,
Japan
,
levodopa
,
Male
,
Middle Aged
,
Movement disorders
,
Parkinson Disease - drug therapy
,
Parkinson's disease
,
randomized controlled trial
,
Treatment Outcome
,
wearing-off
,
zonisamide
Weiterführende Literatur
Empfehlungen zum selben Thema automatisch vorgeschlagen von
bX